NEW YORK, NY / ACCESSWIRE / March 23, 2016 / Islet Sciences, Inc. (OTC: ISLT) ("Islet Sciences"), a biopharmaceutical company focused on developing new technologies and medicines for the early detection, intervention, and pre-treatment to prevent and slow the progression of metabolic disease, today announced that Christian W. Mende, M.D., has joined the Company as Chief Scientific Officer.
Dr. Mende is an esteemed medical practitioner has distinguished himself in the fields of Nephrology, Internal Medicine and Hypertension. He is a Fellow of the American Society of Nephrology, The American College of Physicians, and the American College of Hypertension. Dr. Mende has published extensively in many of the most prestigious national and international peer-reviewed journals. Dr. Mende received his M.D. from the University of Heidelberg, School of Medicine, Heidelberg, Germany.
"The entire team at Islet Sciences is delighted that Dr. Mende has agreed to serve as the Chief Scientific Officer of Islet Sciences," said, John Steel, Director of Islet Sciences, Inc. "His extensive medical career and his comprehensive knowledge of Diabetes will help Islet Sciences through the clinical development process. Having such a talented Physician join our management team will immediately benefit Islet Sciences."
Dr. Mende concluded, "I am honored to serve as Chief Scientific Officer of Islet Sciences. Having devoted my career to metabolic disease, I look forward to leading the Company's Scientific Team into the future."
About Islet Sciences
Islet Sciences, Inc., a biopharmaceutical company based in New York, NY, is developing new medicines and technologies for the treatment of metabolic disease. For more information, please visit http://www.isletsciences.com.
Forward-Looking Statements
Certain statements in this press release constitute forward-looking statements. These statements are not historical facts but instead represent only Islet Science's belief regarding future events, many of which, by their nature, are inherently uncertain and outside Islet Science's control. It is possible that actual results will differ, possibly materially, from the anticipated results indicated in these statements. Factors that could affect Islet Science's financial and other results are included in Islet Science's periodic filings with the SEC pursuant to the Securities Exchange Act of 1934.
CONTACT:
Islet Sciences
John Steel, Director
Phone: + 1 858-692-7897
SOURCE: Islet Sciences, Inc.
